Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 88 clinical trials
Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias

The purpose of this study is to evaluate the safety and efficiency of personalized targeted therapy in combination with high-dose chemotherapy as part of a preparative regimen before T-depleted allogeneic hematopoietic stem cell transplantation in children with chemoresistant acute leukemias

  • 0 views
  • 26 Jan, 2021
  • 1 location
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This will be an open-label, Phase 1B/2A, study to characterize the efficacy, safety, pharmacokinetics, and pharmacodynamics of fosciclopirox administered alone and in combination with cytarabine in patients with R/R AML with up to two cohorts studied to confirm the efficacy (or futility) of fosciclopirox on the endpoint of disease response. …

  • 0 views
  • 14 Jun, 2022
  • 2 locations
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

(AYAs) with relapsed/refractory acute myeloid leukemia (AML). The trial will be done in two phases: Phase 1 will determine the maximum tolerated dose of CD33CART cells using a 3+3 trial design. Phase 2

induction chemotherapy
cyclophosphamide
gilbert's syndrome
ejection fraction
flow cytometry
  • 28 views
  • 26 May, 2022
  • 6 locations
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Researchers plan to enroll a total of 100 patients with relapsed, refractory acute myeloid leukemia (AML) to receive a single dose of autologous CAR T cells.The safety of CAR T therapy was

ejection fraction
remission
  • 0 views
  • 17 Oct, 2021
  • 1 location
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.

  • 0 views
  • 10 Jul, 2022
  • 3 locations
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy. Approximately 20 adult patients with …

  • 0 views
  • 04 Oct, 2022
  • 4 locations
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia

This is an early phase clinical study using NEI-01 as single agent in oncology indication. This is an open label study and it's divided into two parts. Part 1: This part is ascending dose design to determine the safety and tolerability of NEI-01 and find out recommended dose of NEI-01 …

  • 0 views
  • 29 May, 2022
  • 1 location
Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML

patients with relapsed/refractory Acute Myeloid Leukemia (AML) and patients 65 years with initial diagnosis of AML. Primary objectives are: maximum tolerated dose (MTD) and dose

induction chemotherapy
tacrolimus
remission
refractory acute myeloid leukemia (aml)
azacitidine
  • 0 views
  • 12 Jun, 2021
  • 1 location
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back (relapsed), does not respond to treatment (refractory), or has not been treated (untreated). Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine and venetoclax, work in different ways …

  • 3 views
  • 04 Oct, 2022
  • 1 location
IS-free Treg HaploHCT

This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory acute myeloid leukemia (AML) and/or

leukemia
cancer
cyclophosphamide
gilbert's syndrome
myelodysplastic syndromes
  • 0 views
  • 08 Jul, 2022
  • 1 location